Data from two KEYNOTE trials show pembrolizumab benefited patients with advanced SCLC
(American Association for Cancer Research) The anti-PD-1 monoclonal antibody pembrolizumab (Keytruda) showed promising antitumor activity with durable responses in patients with pretreated, advanced small cell lung cancer (SCLC), according to results from a pooled analysis of the two clinical trials, the phase 1b KEYNOTE-028 and the phase II KEYNOTE-158, presented at the AACR Annual Meeting 2019, March 29-April 3. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 1, 2019 Category: Cancer & Oncology Source Type: news
Focus on immunotherapy and patient perspective at IASLC 2019 Small Cell Lung Cancer Meeting
(International Association for the Study of Lung Cancer) While non-small cell lung cancer (NSCLC) is the more common form of lung cancer and attracts the lion's share of the research funding, recent developments in small cell lung cancer may be shifting that slightly. In order to capitalize on these recent developments, researchers who focus on small cell lung cancer (SCLC) will gather in New York City at Memorial Sloan Kettering Cancer April 3-5, 2019, for the IASLC 2019 Small Cell Lung Cancer Meeting. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 29, 2019 Category: International Medicine & Public Health Source Type: news
Lung cancer patient channels diagnosis into lifetime activism
(International Association for the Study of Lung Cancer) The Third Biennial IASLC-sponsored Small Cell Lung Cancer Workshop will be held at Memorial Sloan Kettering Cancer Center in New York City, April 3-5, 2019, and will focus on preclinical and clinical advances in small cell lung cancer (SCLC) research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 21, 2019 Category: Cancer & Oncology Source Type: news
FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: World Pharma News)
Source: World Pharma News - March 20, 2019 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news
Tecentriq Approved for Small Cell Lung Cancer
TUESDAY, March 19, 2019 -- Tecentriq (atezolizumab) has been approved by the U.S. Food and Drug Administration to treat adults with extensive-stage small cell lung cancer (ES-SCLC).
The drug has been approved as a first-line treatment for the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 19, 2019 Category: General Medicine Source Type: news
FDA approves Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Media News)
Source: Roche Media News - March 19, 2019 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - March 19, 2019 Category: Pharmaceuticals Source Type: news
Prophylactic cranial irradiation: Improvements for advanced NSCLC
(NRG Oncology) Prophylactic cranial irradiation (PCI), a technique used to prevent the clinical development of brain metastases, is established as a standard approach for many patients with small cell lung cancer (SCLC) after initial therapy. While studies established that PCI decreases the incidence of brain metastases for patients with locally advanced non-small cell lung cancer (LA-NSCLC), there is no established indication for its use for such NSCLC patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 18, 2019 Category: Cancer & Oncology Source Type: news
Sharp Drop in Prophylactic Brain Irradiation in SCLC
(MedPage Today) -- Survey shows rapid adoption of new data, shift toward MRI surveillance (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 13, 2019 Category: American Health Source Type: news
Sharp Drop in PCI Use for Extensive-Stage SCLC
(MedPage Today) -- Survey shows rapid adoption of new data, shift toward MRI surveillance (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 13, 2019 Category: American Health Source Type: news
Researchers develop human cell-based model to study small cell lung cancer
(Rockefeller University Press) Researchers from Weill Cornell Medicine have used human embryonic stem cells to create a new model system that allows them to study the initiation and progression of small cell lung cancer (SCLC). The study, which will be published February 8, 2019 in the Journal of Experimental Medicine, reveals the distinct roles played by two critical tumor suppressor genes that are commonly mutated in these highly lethal cancers. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 8, 2019 Category: Biology Source Type: news
Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition
Small cell lung cancer (SCLC) is a recalcitrant, aggressive neuroendocrine-type cancer for which little change to first-line standard-of-care treatment has occurred within the last few decades. Unlike nonsmall cell lung cancer (NSCLC), SCLC harbors few actionable mutations for therapeutic intervention. Lysine-specific histone demethylase 1A (LSD1 also known as KDM1A) inhibitors were previously shown to have selective activity in SCLC models, but the underlying mechanism was elusive. Here, we found that exposure to the selective LSD1 inhibitor ORY-1001 activated the NOTCH pathway, resulting in the suppression of the transcr...
Source: Signal Transduction Knowledge Environment - February 5, 2019 Category: Science Authors: Augert, A., Eastwood, E., Ibrahim, A. H., Wu, N., Grunblatt, E., Basom, R., Liggitt, D., Eaton, K. D., Martins, R., Poirier, J. T., Rudin, C. M., Milletti, F., Cheng, W.-Y., Mack, F., MacPherson, D. Tags: STKE Research Articles Source Type: news
Patients With Lower-Stage Small-Cell Lung Cancer Do Better Patients With Lower-Stage Small-Cell Lung Cancer Do Better
Patients with stage I to II small-cell lung cancer (SCLC) treated with chemoradiotherapy have better outcome than those with stage III disease, according to a secondary analysis of a randomized clinical trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news
FDA grants priority review to Roche's Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES - SCLC). (Source: World Pharma News)
Source: World Pharma News - December 6, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news
Roche's Tecentriq wins speedy U.S. review in small cell lung cancer
Roche's Tecentriq immunotherapy with chemotherapy won priority review in the United States for the initial treatment of extensive-stage small cell lung cancer (SCLC), the company said, setting up possible approval by March 18. (Source: Reuters: Health)
Source: Reuters: Health - December 5, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
